HODO-2206 is under clinical development by Hyundai Pharma and currently in Phase I for Idiopathic (Essential) Hypertension. According to GlobalData, Phase I drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HODO-2206 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HODO-2206 is under development for the treatment of idiopathic (essential) hypertension. It is administered by oral route.
Hyundai Pharma overview
Hyundai Pharma develops, manufactures and distributes pharmaceutical products, health drinks and medical equipment. The company provides over the counter and prescription drugs in the forms of tablets, capsules, solutions for injections and infusions, suspensions, ointments, creams, gels, and others. It is investigating HDNO-1605, an antidiabetic drug for type 2 diabetes; BPDO-1603 and HDDO-1728 for the treatment of senile dementia. Hyundai Pharma offers products in the therapeutic areas of cardio-vascular, respiratory, endocrinology, central nervous system (CNS), obstetrics or gynecology, gastro-intestinal, dermatology and cancer. The company markets its products through partners and distributors worldwide. Hyundai Pharma is headquartered in Seoul, South Korea.
For a complete picture of HODO-2206’s drug-specific PTSR and LoA scores, buy the report here.